The clinical trials arena is becoming increasingly data-driven, with demand growing for sponsors to have real-time data access and ongoing updates throughout a study rather than just a final report.
The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.
This analysis is by Bloomberg Intelligence Industry Analyst Andrew Galler and Senior Associate Analyst Jack Maltby. It appeared first on the Bloomberg Terminal. Clinical trials represent a significant ...
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support ...
This article is part of our series on clinical data considerations. Read How to Approach Fundraising and Investor Relations. When it comes to disclosing clinical trial data in the biotechnology arena, ...
The MarketWatch News Department was not involved in the creation of this content. Collaboration provides country-specific standard of care data, disease-specific prevalence, and industry benchmarking ...
Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies and expansion of site networks, predicts Velocity Clinical Research CEO and ...
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback